State Street’s Cyclerion Therapeutics CYCN Stock Holding History

State Street’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,771	Closed	-$50.1K	–	4688
2023 Q1	$50.1K	Hold	5,771	–	–	﹤0.01%	4502
2022 Q4	$75.7K	Hold	5,771	–	–	﹤0.01%	4448
2022 Q3	$99K	Hold	5,771	–	–	﹤0.01%	4467
2022 Q2	$63K	Sell	5,771 -6	-0.1%	-$86	﹤0.01%	4673
2022 Q1	$128K	Buy	5,777 +236	+4%	+$5.68K	﹤0.01%	4558
2021 Q4	$191K	Buy	5,541 +1,055	+24%	+$49.8K	﹤0.01%	4373
2021 Q3	$275K	Buy	4,486 +320	+8%	+$20.9K	﹤0.01%	4233
2021 Q2	$325K	Sell	4,166 -15,841	-79%	-$992K	﹤0.01%	4022
2021 Q1	$1.12M	Sell	20,007 -1,358	-6%	-$102K	﹤0.01%	3599
2020 Q4	$1.31M	Sell	21,365 -589	-3%	-$40.2K	﹤0.01%	3508
2020 Q3	$2.67M	Sell	21,954 -3,050	-12%	-$349K	﹤0.01%	3084
2020 Q2	$2.96M	Sell	25,004 -1,862	-7%	-$156K	﹤0.01%	3020
2020 Q1	$1.42M	Buy	26,866 +533	+2%	+$38K	﹤0.01%	3199
2019 Q4	$1.43M	Buy	26,333 +3,682	+16%	+$344K	﹤0.01%	3341
2019 Q3	$5.49M	Buy	22,651 +1,294	+6%	+$280K	﹤0.01%	2739
2019 Q2	$4.89M	Buy	+21,357	New	+$6.04M	﹤0.01%	2832

Other funds holding CYCN

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street's CYCN Position: Q2 2023 in Review

State Street sold out of Cyclerion Therapeutics (CYCN) in Q2 2023, closing a stake of 5,771 shares — an estimated $50.1K sold.

State Street first reported a position in CYCN in Q2 2019 and held it in 16 quarters. The position peaked at $5.49M in Q3 2019. 18 funds tracked by Wall St. Rank hold CYCN as of Q2 2023.

State Street reported no remaining Cyclerion Therapeutics position as of Q2 2023 after selling out during the quarter.
State Street sold 5,771 Cyclerion Therapeutics shares in Q2 2023, an estimated $50.1K.
State Street first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 16 quarters.
State Street's Cyclerion Therapeutics position peaked at $5.49M in Q3 2019.
18 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2023.

Based on State Street's 13F filing for Q2 2023, filed 14 Aug 2023.